Principal investigator

Olatec Therapeutics to Conduct a Phase 2 Clinical Trial in Patients with Early Parkinson’s Disease with its NLRP3 Inhibitor, Dapansutrile

Retrieved on: 
Tuesday, February 20, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Dopaminergic, Inflammation, Neuron, NLRP3, Principal investigator, Neurodegenerative disease, University, Therapy, CNS, Patient, Cell damage, Disease, Substantia nigra, Movement, Microglia, Brain, Pharmaceutical industry

Olatec Therapeutics, Inc. (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced that Cure Parkinson’s granted an award to initiate a Phase 2 clinical trial investigating the potential of oral dapansutrile to slow or stop the progression of Parkinson’s disease.

Key Points: 
  • Olatec Therapeutics, Inc. (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced that Cure Parkinson’s granted an award to initiate a Phase 2 clinical trial investigating the potential of oral dapansutrile to slow or stop the progression of Parkinson’s disease.
  • Parkinson’s is a complex neurodegenerative disease, which as reported by Cure Parkinson’s, is the fastest growing neurological condition in the world.
  • Treatment with dapansutrile has the potential to arrest this cyclical process of cell damage thereby slowing the progression of the disease.
  • The trial will seek to enroll 36 participants with early Parkinson’s disease.

The Inner Circle acknowledges Nana E. Tchabo, MD, FACOG as a Pinnacle Life Member

Retrieved on: 
Thursday, March 7, 2024
Theta, Overlook Medical Center, Woman, Professional, Inner circle, Doctor of Philosophy, Multimedia, MD, Georgetown University, Education, Immunotherapy, Pathology, Thomas Jefferson University, Uterine cancer, ABOG, Parent, Principal investigator, Radiation, National Cancer Institute, Women's studies, Gynecologic Oncology (journal), Health, FACOG, Oncology nursing, Brown University, Vaginal cancer, Ovarian cancer, Associate, Gestational trophoblastic disease, Women's health, Biology, Mount Sinai School, Estate (law), Delta Sigma, Research, Carol, Medication

CHESTER, N.J., March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.

Key Points: 
  • CHESTER, N.J., March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.
  • Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience and a minor in Women's Studies.
  • She then attended the Warren Alpert Brown University School of Medicine, where she was cited for academic excellence.
  • Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health System Morristown and Overlook Medical Centers.

Perimeter Medical Imaging AI Reports Its Proprietary Artificial Intelligence Algorithm + OCT Identified 96.8% of Positive Breast Cancer Margins in Newly Published Peer Reviewed Study

Retrieved on: 
Thursday, February 29, 2024
Breast cancer, Perimeter, Baylor University, Neoplasm, Fusion, OTC, PINK, Principal investigator, Data, Breast, Medicine, Medical imaging

2023; 13(12):2340. https://doi.org/10.3390/life13122340

Key Points: 
  • 2023; 13(12):2340. https://doi.org/10.3390/life13122340
    From a clinical perspective, the deep learning model showed high levels of sensitivity and specificity, accurately identifying 96.8% of pathology-positive margins.
  • These results highlight the clinical viability of AI-enhanced margin visualization using WF-OCT in breast cancer surgery and its potential to decrease reoperation rates due to residual tumors.
  • Adrian Mendes, Perimeter's Chief Executive Officer, stated, "We have a training dataset of several million proprietary images of both cancerous and healthy tissue captured with our OCT imaging technology.
  • Perimeter intends to conduct a planned interim analysis in the second quarter of 2024, with study completion anticipated by the end of 2024.

Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Retrieved on: 
Friday, February 16, 2024
Nervous system, POC, AMIX, Collateral damage, Pain, Principal investigator, Patient, Disease, Trial of the century, Ethanol, Medical imaging

THE WOODLANDS, TX, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the completion of its site initiation for its proof-of-concept human clinical study evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Key Points: 
  • “We continue to make solid progress with our PoC human clinical study.
  • This study is a very important step in validating our clinical and regulatory plans for our technology and as such our team is dedicated to its successful execution.
  • The primary objective of the proof-of-concept human clinical study is to successfully ablate relevant somatic nerves and mitigate pain in patients with pancreatic cancer pain utilizing RF ablation in a transvascular approach to the nerves in the region.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the study.

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Retrieved on: 
Thursday, February 15, 2024
Neoplasm, Doctor of Philosophy, Immunotherapy, SCCA, News, Pharmaceutics, Destiny, PR, Optimism, Poster, Anal cancer, Pancreatic cancer, Anal, CEACAM6, Brigham and Women's Hospital, Bristol Myers Squibb, Therapy, Immune system, Pelareorep, International, Breast cancer, Fast track (FDA), Serology, AIO, Hospital, Hope, Principal investigator, HGG, Conference, Safety, Biomarker, Tumor microenvironment, Patent, Clinical trial, Survival, Harvard Medical School, Acute lymphoblastic leukemia, Injection, MSI, MD, BioNTech, FDA, TSX, Cancer, Entrepreneurship, Prevalence, American depositary receipt, Anal canal, Patient, Cone Health Women's Hospital, ONC, Pharmaceutical industry

According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."

Key Points: 
  • According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."
  • Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is developing pelareorep, a unique immunotherapy with the power to awaken the immune system and unlock its antitumor potential.
  • It is committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
  • Bristol-Myers Squibb and Fate Therapeutics are some of the other key patent filers in cancer immunotherapy."

Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033

Retrieved on: 
Thursday, February 15, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Clinical Trials, SARS-CoV-2, Doctor of Philosophy, AP-HP, MD, Coronavirus, Principal investigator, Vaccine, Frontiers, Safety, Trial of the century, Ageing, CIC

Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that the first participant has been vaccinated in its new Phase 1 trial ( NCT06128382 ) evaluating OVX033, a broad-spectrum sarbecovirus vaccine candidate.

Key Points: 
  • Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that the first participant has been vaccinated in its new Phase 1 trial ( NCT06128382 ) evaluating OVX033, a broad-spectrum sarbecovirus vaccine candidate.
  • In a rabbit toxicology study, the vaccine candidate also showed an excellent safety and tolerance profile after intramuscular administration.
  • One single dose of OVX033 vaccine or of placebo will be administered intramuscularly in 48 healthy subjects aged 18-49 years.
  • OVX033 is based on Osivax’ cutting-edge technology, OligoDOMTM, which has already established promising proof-of-concept data with OVX836, a broad-spectrum influenza A vaccine candidate currently being evaluated in several Phase 2 clinical studies.

Eden Announces $1.4 Million in ARPA-E Awards to Develop Stimulated Geologic Hydrogen Technologies

Retrieved on: 
Tuesday, February 13, 2024
Environment, Other Science, Research, Public Policy, Sustainability, Finance, Hardware, Professional Services, Science, Other Natural Resources, Technology, Mining, Minerals, Government, Other Energy, Utilities, Oil, Gas, Alternative Energy, Natural Resources, Energy, Hydrogen, ARPA, ERS, Iron, Permeability, Temperature, Mechanical, Principal investigator, Entrepreneurship, Carbon, University, Samail Ophiolite, Mineral, Fracture

The funding is part of the $20M ARPA-E Geologic Hydrogen program, which prioritizes funding new technologies that stimulate generation of hydrogen in the subsurface, with an emphasis on minimizing costs and reducing environmental footprint.

Key Points: 
  • The funding is part of the $20M ARPA-E Geologic Hydrogen program, which prioritizes funding new technologies that stimulate generation of hydrogen in the subsurface, with an emphasis on minimizing costs and reducing environmental footprint.
  • Eden will develop novel stimulated geologic hydrogen technologies to boost production from iron-rich formations like peridotites and develop game-changing solutions for long-term electrical energy storage in geological formations.
  • Model predictions reveal that the global geologic hydrogen potential exceeds millions of megatonnes (Mt) , and only a portion of it is capable of meeting the projected hydrogen demand for centuries.
  • One innovative approach to enhancing permeability in geologic hydrogen reservoirs is through Eden's ground-breaking Electrical Reservoir Stimulation (ERS) technology.

IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16

Retrieved on: 
Tuesday, February 13, 2024
Hospital, HMO, Health, Infrared, Trial of the century, Principal investigator, Death, Conference, Safety, Rabin Medical Center, Patient, Clalit Health Services, Medical device

The single arm, bi-center, open label, safety and efficacy study evaluated PressureSafe ™ , IR-MED’s decision support device, which uses infra-red spectroscopy combined with an AI-based algorithm to diagnose Stage 1 pressure injuries, compared to standard of care visual and tactile inspection.

Key Points: 
  • The single arm, bi-center, open label, safety and efficacy study evaluated PressureSafe ™ , IR-MED’s decision support device, which uses infra-red spectroscopy combined with an AI-based algorithm to diagnose Stage 1 pressure injuries, compared to standard of care visual and tactile inspection.
  • IR-MED’s clinical and execute team will demonstrate PressureSafe at booth #102 at NPIAP 2024, which is attended by the world’s top thought leaders and practitioners in the prevention and treatment of pressure injuries.
  • Pressure injuries cost the U.S. healthcare system $26.8 billion and lead to 60,000 deaths annually.
  • PressureSafe was found to be over 90% accurate in detecting pressure injuries based on interim results from a multicenter study.

CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

Retrieved on: 
Tuesday, February 13, 2024
Injection, Doctor of Philosophy, Fast track (FDA), MD, Serology, FDA, Food, Hospital, CADL, Hope, Principal investigator, HGG, Therapy, Tumor microenvironment, Patient, Clinical trial, Survival, Harvard Medical School, Pharmaceutical industry

“Receiving FDA Fast Track Designation for CAN-3110 reinforces the critical need to find effective treatment options for patients with recurrent HGG and further supports the potential of CAN-3110 to address the challenges that the standard of care and conventional therapies have failed to meet,” said Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel.

Key Points: 
  • “Receiving FDA Fast Track Designation for CAN-3110 reinforces the critical need to find effective treatment options for patients with recurrent HGG and further supports the potential of CAN-3110 to address the challenges that the standard of care and conventional therapies have failed to meet,” said Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel.
  • “As recently published in Nature, a strong local and systemic anti-tumoral response and improved survival in patients with recurrent HGG was observed following a single injection of CAN-3110.
  • Positive HSV-1 serology was a predictor of response and was associated with improved survival (mOS in this population reached 14 months).
  • “With Fast Track Designation, I look forward to the potential of accelerating the development of CAN-3110 and the possibility of bringing this differentiated therapy to patients with recurrent high-grade glioma as we strive to improve outcomes and provide hope for patients and their families.”

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

Retrieved on: 
Friday, February 9, 2024
Tufts Medical Center, MD, Pain, Investigational New Drug, FDA, Food, DED, Principal investigator, IND, Clinical trial, Patient, NCP, Disease, Pharmaceutical industry

Notably, the initial IND submission to FDA proposed an open-label design for the clinical trial.

Key Points: 
  • Notably, the initial IND submission to FDA proposed an open-label design for the clinical trial.
  • Based on positive feedback from FDA, the Phase 2 study is now designed as a double-masked, randomized, 12-week placebo-controlled trial comparing OK-101 to placebo in NCP patients.
  • A total of 54 patients are planned for the study, with NCP disease confirmed via confocal microscopy.
  • OK-101 was also shown in a cutting-edge mouse model of NCP to significantly reduce ocular neuropathic pain.